Insights su Testing e Conformità
Guide esperte su analisi di laboratorio, accreditamento UNI CEI EN ISO/IEC 17025, conformità FDA e sistemi qualità per produttori e brand.
What FDA Inspectors Actually Look for in GMP Training Records — And How AI Is Changing What's Possible
GMP training deficiencies are a perennial FDA 483 citation. Here's what inspectors check under 21 CFR 211.25 — and how AI closes the gaps before they do.
Thirty Years After Barr Labs: What FDA Still Expects From Your OOS Investigation Program
The 1993 Barr Laboratories ruling shaped FDA's entire OOS standard. Here's what 21 CFR 211.192 actually requires — and where manufacturers still stumble in 2026.
What FDA Consent Decrees Really Cost — And How AI-Augmented Compliance Consulting Shortens the Road Back
FDA consent decrees cost regulated manufacturers $50M–$150M and years of production restrictions. Here's what they mean operationally, and how AI-augmented regulatory compliance consulting changes recovery.
FDA Sponsor Inspections: The Adverse Event Reporting Failures That Keep Triggering 483s
FDA's BIMO program consistently cites sponsors for IND safety reporting failures under 21 CFR 312.32. Here's what auditors find—and how to close the gaps before they arrive.
21 CFR 202.1 Fair Balance: The Rx Advertising Standard Behind Most OPDP Enforcement Letters — And What AI Review Changes
21 CFR 202.1 fair balance requirements explained—and how AI-augmented promotional review audits catch the violations that cost pharma companies millions.
FDA Expectations for AI/ML Software Validation in GxP Environments
FDA's CSA guidance and GAMP5 don't fully address AI/ML systems in GxP. Here's what regulated manufacturers need to validate compliantly in 2026.
When Your AI Tool Becomes a Medical Device: FDA's SaMD Framework and Audit Readiness
How FDA classifies Software as a Medical Device, what the 2026 QMSR final rule changes for AI quality systems, and how to build audit-ready documentation under 21 CFR 820.
FDA's QSIT Framework: What Inspectors Actually Evaluate in Your Quality System
FDA's QSIT framework governs how inspectors evaluate your quality system. Learn what changed under the 2026 QMSR transition and how to prepare.
How AI Is Transforming the Annual Product Review Process Under 21 CFR 211.180(e)
FDA's 21 CFR 211.180(e) APR requirement still triggers 483s at well-run sites. See how AI-augmented review is closing the compliance gap — and cutting cycle time.
FDA 483 Observations: What the Data Reveals — and How AI Catches Them First
FDA 483 observations precede nearly every warning letter. Learn the top recurring categories, why internal audits miss them, and how AI-augmented readiness changes the outcome.
ICH E6(R3) Is Now Shaping FDA GCP Inspections — Here's What Sponsors Must Change
ICH E6(R3) is reshaping FDA GCP inspection expectations. A practical guide for sponsors and CROs to close RBQM compliance gaps and pass BIMO audits.
FDA Warning Letters for Drug Advertising: What the Patterns Tell Us About Your Compliance Risk
OPDP warning letters reveal predictable patterns. Learn the six most common FDA drug advertising violations and how to audit your own promotional materials.
FDA Auditors and ALCOA+: What Your Lab Software Systems Must Prove
FDA inspectors are scrutinizing ALCOA+ compliance in lab software harder than ever. Learn exactly what auditors check — and how to make your CSV documentation audit-ready.
FDA's Predetermined Change Control Plan: What AI Medical Device Makers Must Lock In Before Submission
FDA finalized PCCP guidance for AI/ML medical devices in December 2024. Here's what your submission must include — and what happens if you skip it.
The 5 Document Control Failures That Draw FDA Warning Letters — And How to Fix Them
Document control deficiencies top FDA inspection findings year after year. Here's what regulated companies keep getting wrong — and what regulatory compliance consulting actually fixes.
Cleaning Validation Acceptance Criteria: The Worst-Case Approach FDA Expects — and Where Manufacturers Keep Stumbling
Beyond the 10 ppm default: how HBEL-derived limits, MACO calculations, and recovery studies hold up under FDA's 21 CFR 211.67 cleaning validation scrutiny.
Before the FDA Calls: Understanding Class I, II, and III Recall Classifications
Learn how FDA classifies recalls — Class I, II, and III — and what each means for your recall strategy, timeline, and regulatory compliance obligations.
Decentralized Clinical Trials: The FDA Remote Monitoring Compliance Gaps Most Sponsors Miss
FDA's 2023 DCT guidance created new obligations many sponsors aren't meeting. Here's what BIMO inspectors are looking for — and how to close the gaps.
Supplier Qualification for Pharmaceutical Manufacturing: What Your GMP Program Is Missing
Most pharma supplier qualification programs have hidden gaps the FDA will find. Here is what 21 CFR Part 211 requires and how to build a defensible risk-based program.
OTC Drug Facts Panel Compliance: The Labeling Errors That Trigger FDA Warning Letters
FDA warning letters for OTC drug labeling violations are more common than manufacturers expect. Here's what 21 CFR 201.66 requires — and where companies keep getting it wrong.
Excel Spreadsheet Validation in GMP: Why FDA Auditors Are Looking Harder in 2026
FDA 483 observations for unvalidated GMP spreadsheets are rising. Here's what 21 CFR Part 11, GAMP5, and current FDA thinking actually require — and how to fix your gaps fast.
QMSR Is Live: What FDA Device Auditors Are Checking Right Now
The QMSR compliance deadline passed February 2, 2026. Here's exactly what FDA investigators are scrutinizing in medical device QMS audits today.
The Document Control Failures That Generate the Most FDA 483 Observations — And How to Close Them
Which document control gaps trigger the most FDA 483 observations under 21 CFR 211 and the new QMSR — and how to close them before your next inspection.
Environmental Monitoring in Aseptic Manufacturing: What FDA Actually Expects
FDA cites environmental monitoring deficiencies in roughly 1 in 4 warning letters to sterile manufacturers. Here's what 21 CFR 211 actually requires.
FDA Enforcement in 2026: Medical Devices, Supplements, and Imports Are in the Crosshairs
FDA inspections are surging in 2026. See which industries face the most scrutiny and how regulatory compliance consulting can protect your operations.
GCP Audit Readiness: The ICH E6(R2) Gaps FDA Inspectors Cite Most Often
Five finding categories that dominate FDA BIMO inspections under ICH E6(R2) — and practical steps sponsors and CROs must take before the next audit.
FDA's Social Media Rules for Prescription Drug Promotion: What Pharma Brands Must Know in 2026
FDA's OPDP is scrutinizing social media drug promotions more than ever. Here's what pharma brands must review before their next campaign goes live.
GAMP5 Second Edition: What Changed and Why Your Validation Strategy Needs to Catch Up
The 2022 GAMP5 Second Edition rewrote the rules on GxP software validation. Here's what actually changed and how to align your program with FDA's current expectations.
The 5 CAPA Mistakes That Trigger FDA 483 Observations (And How to Fix Them)
CAPA deficiencies top FDA 483 citations year after year. Learn the five structural mistakes that trigger observations — and how to fix them before your next inspection.
FDA Process Validation Stages 1–3: A Practical GMP Guide for 2026
How FDA's three-stage process validation lifecycle framework works in practice — and the Stage 3 failures still triggering warning letters in 2026.
Why Most CAPA Systems Fail FDA Inspections — And How to Build One That Doesn't
Learn why CAPA systems fail FDA inspections, what 21 CFR 820.100 requires, and how to build corrective and preventive action programs that actually work.
21 CFR Part 820 Design Controls: What FDA Investigators Look For in a QSR Audit
A practical guide to 21 CFR 820.30 design controls and the five sub-elements FDA investigators probe most during QSR audits of medical device manufacturers.
FDA's Risk-Based Inspection Model: How Your Facility Gets Selected — And How to Stay Ready
Learn how FDA's Site Selection Model determines inspection frequency and get a practical 6-step regulatory compliance readiness guide for your facility.
Why Your CAPA System Fails FDA Inspection — And How to Fix It Before the 483 Arrives
FDA 483s cite CAPA deficiencies more than almost any other GMP issue. Here's what investigators look for under 21 CFR 820.100 — and how to close the gaps.
FDA Form 483 Observations: The 6 Most Common Inspection Findings — and How to Fix Them Before They Become Warning Letters
Discover the 6 most cited FDA 483 inspection findings in drug and device manufacturing, why some escalate to Warning Letters, and a step-by-step remediation framework.
FDA's Decentralized Clinical Trial Framework: An Audit Readiness Guide for 2026
FDA's 2023 DCT guidance is now being enforced. This audit readiness guide covers the five areas BIMO inspectors focus on and the documentation every DCT sponsor needs.
FDA Drug Advertising Warning Letters: What Your Promotional Review Process Is Missing
OPDP warning letters for drug advertising follow predictable patterns. This audit guide breaks down the top violations and what a defensible review process looks like.
Validating Cloud-Based Software in GxP Environments: What FDA Expects in 2026
FDA still owns your cloud validation obligation. Learn what 21 CFR Part 11, GAMP5, and FDA's CSA framework require for SaaS and hosted GxP systems in 2026.
FDA QMSR Gap Assessment: A 2026 Inspection Readiness Guide for Medical Device Manufacturers
The QMSR compliance deadline passed February 2, 2026. Use this step-by-step gap assessment framework to prepare for FDA inspections under the new Quality Management System Regulation.
Building a Supplier Qualification Program — A Framework That Scales
A practical framework for building a supplier qualification program that satisfies FDA GMP requirements, scales with business growth, and creates a defensible audit trail for regulatory inspections.
Food Safety Testing Under FSMA — Pathogen, Allergen, and Environmental Monitoring for Manufacturers
A practical guide to food safety testing requirements under FSMA for manufacturers — covering pathogen testing, allergen verification, environmental monitoring programs, and how to select a qualified food testing laboratory.
Hiring an ISO 9001 Consultant — What Manufacturers Should Evaluate Before Signing a Contract
A practical guide for manufacturers on selecting an ISO 9001 consultant — covering qualifications to verify, red flags to avoid, realistic timelines and costs, and how to ensure the QMS actually works after certification.
Lead Testing for Consumer Products and Painted Surfaces — CPSC Limits, Methods, and Compliance
A detailed guide to lead testing requirements for consumer products under CPSC regulations — covering 90 ppm paint limits, 100 ppm substrate limits, XRF vs ICP methods, and compliance strategies for importers and manufacturers.
PFAS Testing for Water and Consumer Products — What Manufacturers Need to Know
A technical guide to PFAS testing requirements for water systems, consumer product manufacturers, and importers — covering EPA 533, EPA 537.1, state regulations, and how to select a qualified PFAS testing laboratory.
Toy Safety Testing — CPSIA, ASTM F963, and What Every Brand Needs Before Selling Children's Products
A comprehensive guide to toy safety testing requirements under CPSIA and ASTM F963 for manufacturers, importers, and brands — covering lead limits, phthalate restrictions, third-party testing, and Children's Product Certificates.
Water Quality Testing for Municipalities, Private Wells, and Commercial Facilities
A practical guide to water quality testing programs for municipalities, private well owners, and commercial facilities — covering EPA methods, contaminant panels, compliance schedules, and how to select a certified water testing laboratory.
ISO 9001 Certification Consultants: How the Process Works
ISO 9001 certification consultants guide you from gap analysis to passing your audit. Here is exactly what the process looks like, how long it takes, and what each phase costs.
Laboratory Consulting Services: What a TIC Consultant Actually Does
Laboratory consulting services help manufacturers, brands, and testing organizations navigate lab selection, ISO accreditation, compliance, and quality systems. Here is what a TIC consultant does and when you need one.
Regulatory Compliance Consulting: When You Need It and What It Costs
Regulatory compliance consulting helps manufacturers, labs, and brands navigate FDA, ISO, and industry-specific requirements. Learn when to hire a consultant, what they do, and what to budget.
Stability Testing Protocols — What Manufacturers Need to Know Before They Start
A manufacturer-focused guide to stability testing protocols: how to design a stability program, which conditions to use, what to test for, and how stability data supports expiration dating and regulatory compliance.
How to Read an ISO 17025 Accreditation Scope — What It Tells You About a Lab
A practical guide to reading and interpreting ISO 17025 accreditation scope documents: what the fields mean, what to look for, and how to use scope documents in lab qualification decisions.
Single Lab vs. Multi-Lab Testing Strategy — How to Choose the Right Approach
A decision framework for manufacturers choosing between a single-lab and multi-lab testing strategy: when each approach makes sense, the trade-offs, and how to manage lab relationships at scale.
FDA Warning Letters in the Supplement Industry — Common Themes and How to Avoid Them
An analysis of recurring themes in FDA warning letters to dietary supplement manufacturers under 21 CFR Part 111, with practical guidance on building systems that prevent the most common violations.
TIC Consulting — When to Hire a Consultant and What to Expect
A practical guide for manufacturers on when TIC consulting adds genuine value, what a qualified consultant should deliver, and how to evaluate consulting engagements before committing.
How to Build a Testing Program for a New Product Launch — Step by Step
A step-by-step framework for building a testing program before a new product launch: from specification development through lab selection, method validation, and release testing.
FDA 21 CFR Part 111 — What Dietary Supplement Manufacturers Must Know
A practical guide to FDA 21 CFR Part 111 GMP requirements for dietary supplement manufacturers: what the regulation covers, where companies commonly fall short, and how to build a compliant testing program.
ISO/IEC 17025 Accreditation — What It Means and Why It Matters for Manufacturers
A plain-language guide to ISO/IEC 17025:2017 accreditation for manufacturers: what it covers, what it does not, and how to use it in lab selection and supplier qualification.
How to Qualify a Testing Laboratory — A Manufacturer's Practical Checklist
A manufacturer-focused checklist for qualifying testing laboratories: accreditation, scope verification, method validation, turnaround times, and red flags to avoid.